Such instability can undermine treatment progress, reduce medication efficacy, and lead to a worsening of the overall condition. For someone already vulnerable to depression, this can bromide detox prolong and intensify symptoms, making it harder to find motivation or seek help. As the initial stimulant effects wear off, alcohol suppresses brain activity, leading to feelings of sadness, fatigue, and hopelessness. This interference can disrupt the equilibrium that medications and therapy aim to maintain, making mood swings more frequent and severe.

Similarly, complex patterns may also result from interactions with medical comorbidities and deserve further study. Thirdly, key clinical variables, such as number of past episodes and, more importantly, time of abstinence were not recorded in all studies. Secondly, the timing of examination widely differs between studies and not all of them have assessed patients during euthymia. Firstly, the sample size in most cases is relatively modest, especially regarding the comorbid BD-AUD groups, which may reflect the difficulty in recruiting clinically stable and motivated patients who consent going through burdensome evaluations. Moreover, the authors did not aim to compare dual and non-dual patients and even the rate of comorbid AUDs was not reported.

Treatment Strategies in Comorbid BD and AUD—General Principles of Treatment

Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. Family treatment for bipolar disorder and substance abuse in late adolescence. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders.

This narrative review tries to summarize current knowledge about the incidence, influence and treatment of illicit drug abuse in people with BD. However, these subjects may also suffer from cyclothymic or bipolar II disorders (BD II). Treating SUD in bipolar disorder requires a comprehensive and multidisciplinary approach. Incidence and management of illicit drug use differ from alcohol use disorders, nicotine use of behavioral addictions. It is only through demonstration of the effectiveness of treatment integration that there will be extensive therapeutic efforts to bridge psychiatric treatment programmes and services, and substance abuse treatment programmes and services.

• For AUD, however, a recent meta-analysis of 22 studies showed no difference between BD-I (OR 3.78) and BD-II (OR 3.81) (28).
• The unpredictability of alcohol’s impact on bipolar mood swings lies in its dual nature as both a stimulant and depressant.
• At Asana Recovery, we specialize in comprehensive dual-diagnosis treatment, offering a personalized approach to help you break free from the cycle of alcohol addiction and bipolar instability.
• If you are ready to find treatment options for yourself or a loved one, get started right now with our free rehab locator tool.
• Cannabis and mood disorders.

In integrated treatment, a clinician or group of clinicians treats both disorders simultaneously. Although the patients receive expert care for each disorder, they may hear potentially conflicting advice regarding the overlap between the two disorders. Parallel treatment, which ordinarily takes place on an outpatient basis, consists of treating the two disorders in separate settings. As a result, little psychotherapy research has focused on patients with co-occurring BD and alcohol dependence. Similarly, motivational enhancement therapy, twelve-step facilitation therapy, and cognitive-behavioral relapse prevention therapy have all been shown to be effective in the treatment of alcohol dependence (Project MATCH Research Group, 1997). In early to mid-adolescence, initiation of alcohol use may be an environmental effect (with social and peer influences being predominant and changeable)(Smyth et al., 2011), but development of the alcohol abuse/dependence pattern in late adolescence or in early adulthood, may be subject to genetic influences (Kendler et al., 2009).

Treatment of Comorbid Bipolar Disorder and Alcoholism

Moreover, extensive use of amphetamines or cocaine may also mimic manic symptoms or may be a risk factor for a switch into a manic episode in a primarily bipolar subject. Milder mood symptoms including depressive or euphoric mood swings may, in many instances, be the result of substance use. When conceptualizing this article, the authors noticed that there is hazleton treatment services a fair number of reviews on alcohol use disorder in individuals with BD, including their own recent publication , whereas there is a relative paucity of up-to-date, comprehensive reviews on the subject of bipolarity and illicit drugs. Besides a strong association between alcohol and nicotine dependence and BD , the abuse of other drugs, such as cocaine, amphetamines, opiates, cannabis, and prescription medications is also an important health concern in people with BD. BD is a risk factor for addictions, both behavioral, such as gambling and substance use disorders . Synopsis of data provides limited evidence that lithium and valproate are effective for the treatment of mood symptoms in cannabis users and may reduce substance use.

Substance use disorders (SUD) are highly prevalent in bipolar disorder (BD) and significantly affect clinical outcomes. In a small open-label trial of acamprosate added to a mood regimen in participants with BD and alcohol dependence, acamprosate produced a significant reduction in number of drinks per week, but no differences in mood symptoms when compared to placebo (Tolliver et al., 2009). In a randomized twelve-week trial of naltrexone and disulfiram for alcohol use in 254 participants with alcohol dependence and co-occurring Axis I disorders (including 19.3% with BD), the medications produced significantly more weeks of abstinence and less craving than placebo (Petrakis et al., 2005). In a randomized, double-blind, placebo controlled trial of quetiapine added to a regimen to treat BD in 115 outpatients with BD and alcohol abuse or dependence, Brown et al. (2008) found that the addition of quetiapine did not result in differences in alcohol use or on scores on the Young Mania Rating Scale (YMRS). Pharmacotherapy clinical trials for BD and those for alcohol dependence have often excluded co-occurring disorders in an attempt to reduce confounding variables. If commonalities in the recovery and relapse process in the two disorders can be seen as parallels between the two disorders, the focus on the relationship between the two disorders can be viewed as the intersection between BD and alcohol dependence.

One approach is monitoring alcohol consumption closely, ensuring that drinking does not interfere with medication schedules or sleep hygiene. Seeking professional help, practicing harm reduction strategies, and understanding the impact of bipolar drinking behavior are crucial steps toward stability and recovery. Instead, they may attribute their elevated mood to feeling “socially fearless” or highly productive. That pattern was consistent across individuals, and did not appear at random. Participants with BD II were more likely to continue heavy drinking than those with BD I. Individuals taking benzodiazepines were less likely to maintain high levels of alcohol consumption compared to those not taking these medications. They analyzed Genetics and alcoholism data from 584 people with BD participating in the Prechter Longitudinal Study of Bipolar Disorder, which has been collecting data since 2006.

Treatment Programs

Drinking on bipolar medication can turn one drink into several, especially drinking on an empty stomach. Alcohol also greatly increases the severity of mania, which many who suffer from bipolar find extremely pleasurable. These patterns do not fit into specific labels of the illness, lacking a more efficient way to classify a similar disorder.

Associated Data

As a result of this process, a number of evidence-based psychotherapies have been developed for BD and for alcohol dependence. There are neurochemical abnormalities in both disorders in the serotonin/dopamine pathways, which could suggest a similar pathology in both disorders (Yasseen et al., 2010). Alcohol dependence is also highly genetic (Mayfield et al., 2008), and a wide range of studies confirm that association (Kendler et al., 2009).

Alcohol Help does not endorse any treatment facility or guarantee the quality of care provided, or the results to be achieved, by any treatment facility. Alcohol Help is not a medical provider or treatment facility and does not provide medical advice. Make a free, confidential call to a treatment provider today. Medicine can be prescribed to reduce the uncontrollable state experienced, reducing the motivation to drink alcohol as a coping mechanism.

In the CANMAT guidelines they are only recommended as second-choice in situations where first choice treatments are not indicated or cannot be used, or when first-choice treatments have not worked (89). This recommendation is, by large, based on the CBT studies conducted by Farren et al. The evidence base for suitable psychotherapies in comorbid BD and AUD remains poor. However, treatment adherence and compliance remain a challenge in this special group, since medications are often not taken as prescribed (61) and psychotherapy appointments are often missed.

• Bipolar I disorder is the most severe; it is characterized by manic episodes that last for at least a week and depressive episodes that last for at least 2 weeks.
• About half of people with BD also struggle with alcohol use problems.
• Bipolar disorder patients may feel out of control or disconnected from their lives.
• Bipolar disorder, often called manic depression, is a mood disorder that is characterized by extreme fluctuations in mood from euphoria to severe depression, interspersed with periods of normal mood (i.e., euthymia).
• In a randomized, double-blind, placebo controlled trial of quetiapine added to a regimen to treat BD in 115 outpatients with BD and alcohol abuse or dependence, Brown et al. (2008) found that the addition of quetiapine did not result in differences in alcohol use or on scores on the Young Mania Rating Scale (YMRS).
• A mood disorder that occurs prior to the onset of another psychiatric disorder is called a primary affective disorder.
• Although SUD is one of the most important comorbidities in BD with a significant influence on clinical outcome, there is still a lack both of basic research and clinical trials, allowing for evidence-based and specific best practices.

In summary, both epidemiological and clinical studies confirm the high co-incidence of drug use disorders in bipolar patients. In comparison, rates for unipolar depression are 40.3% for AUD (21% for alcohol dependence) and 17.2% for other substance use disorders. Improving mood symptoms by specific pharmacotherapy for BD may be the initial step to get a grip on drug use and use disorders, but in case of excessive drug consumption, acute detoxification treatment need to be first before specific BD treatments can be started. The FIRESIDE Principles for an integrated treatment of bipolar disorder and alcohol use disorder. In the programmatic level, as exemplified by the work of Farren et al. (Farren and McElroy, 2008, 2010; Farren et al., 2010), patients enter a comprehensive integrated treatment programme that focuses on both psychiatric illness and substance use disorders. Addressing alcohol use is therefore critical in breaking this cycle and restoring stability for individuals with bipolar disorder.

In addition, both disorders have a significantly increased rate of suicides and suicide attempts with an added risk in case of coexistence of both disorders (23–25). SUD comorbidity is not exclusive to adult bipolar patients but starts early in life. Whereas numbers for legal substances, e.g., alcohol, are considered as relatively robust and reproducible, many cases of illicit drug use remain undetected in patients with BD.

The highest rates of comorbid BD and SUD were reported in US samples, the lowest in Asian studies. In a review and meta-analysis of clinical studies, 22 multi-site and 56 individual, mostly single-site studies reporting co-morbidity rates of SUD and BD in inpatients or outpatients were identified by systematic literature search . The association was higher for BD I individuals using illicit drugs compared to bipolar II respondents (ORs 7.48 vs. 3.30).